Submissions from 2015
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer, Paul L. Swiecicki, Lili Zhao, Emily Belile, Assuntina G. Sacco, Douglas B. Chepeha, Irina Dobrosotskaya, Matthew Spector, Andrew Shuman, Kelly Malloy, Jeffrey Moyer, Erin McKean, Scott McLean, Gregory T. Wolf, Avraham Eisbruch, Mark Prince, Carol Bradford, Thomas Carey, and Francis P. Worden
Biosynthetic products from a nearshore-derived gram-negative bacterium enable reassessment of the kailuin depsipeptides, Christine M. Theodore, Nicholas Lorig-Roach, Patrick C. Still, Tyler A. Johnson, Marija Drašković, Joshua A. Schwochert, Cassandra N. Naphen, Mitchell S. Crews, Simone A. Barker, Frederick A. Valeriote, R S. Lokey, and Phillip Crews
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer, Denise A. Yardley, Robert Weaver, Michelle E. Melisko, Mansoor N. Saleh, Francis P. Arena, Andres Forero, Tessa Cigler, Alison Stopeck, Dennis Citrin, Ira Oliff, Rebecca Bechhold, Randa Loutfi, Agustin A. Garcia, Scott Cruickshank, Elizabeth Crowley, Jennifer Green, Thomas Hawthorne, Michael J. Yellin, Thomas A. Davis, and Linda T. Vahdat
HPLC Plasma Assay of a Novel Anti-MRSA Compound, Kaempferol-3-O-Alpha-L-(2 '',3 ''-di-p-coumaroyl)rhamnoside, from Sycamore Leaves, Yiguan G. Zhang, Frederick A. Valeriote, Kenneth Swartz, Ben Chen, Mark T. Hamann, Douglas L. Rodenburg, James D. McChesney, and Jiajiu Shaw
